For a US medical device company looking to understand how UK payers would view their technology, Alacrita conducted desk research to develop the technology’s value proposition. We then convened a payer advisory board, comprising a member of NICE, a director of NHS commissioning and payers from regional NHS trusts,  to understand on what basis payers would evaluate the technology, what comparators would be used and to assess payer’s reactions to the proposed data package based on the currently designed clinical trial and supporting information.

Alacrita is able to access to real payers across Europe responsible for actual reimbursement/approval decisions. By convening a payer advisory board, we are able to gain a wide range of perspectives from diverse payers. We provide the client with a better understanding of the evidence payers need to approve a new medical intervention to and provide clear recommendations as to how companies should go about collecting that data.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch